Table 1.
Demographic, clinical, and laboratory data of SLE and RA patients and controls.
| SLE (n = 117) | % | RA (n = 67) | % | Controls (n = 24) | % | |
|---|---|---|---|---|---|---|
| Age (years, average ± SD) | 37,5 ± 10,41 | 52,65 ± 10,150 | 35,1 ± 9,138 | |||
| Disease time (months, average ± SD) | 105,48 ± 93,83 | 135,70 ± 103,39 | — | |||
| IL-9 levels (pg/mL) | 12,26 ± 25,235 | 4,77 ± 3,618 | 1,22 ± 0,706 | |||
| Gender | ||||||
| Female | 114 | 97,44 | 64 | 95,52 | 24 | 100 |
| Male | 3 | 2,56 | 3 | 4,48 | 0 | 0 |
| Active nephritis | 24 | 20,51 | — | — | — | — |
| Rash | 13 | 11,11 | — | — | — | — |
| Alopecia | 12 | 10,26 | — | — | — | — |
| Anti-DNA positive | 16 | 14,16 | — | — | — | — |
| SLEDAI | 3,31 ± 3,804 | |||||
| SLICC | 1,008 ± 1,276 | — | — | — | — | |
| Positive RF | — | — | 48 | 72,73 | — | — |
| Erosions∗ | — | — | 35 | 52,24 | — | — |
| DAS28 | — | — | 4,84 ± 1,353 | — | — | |
| CDAI | — | — | 20,75 ± 13,453 | — | — | |
| ESR (mm/h) | — | — | 41 ± 22,000 | — | — | |
| Treatment | — | — | ||||
| Corticosteroids | 90 | 77,6 | 51 | 76,1 | — | — |
| Antimalarials | 70 | 60,3 | 13 | 19,4 | — | — |
| Methotrexate | — | — | 44 | 65,7 | — | — |
| Leflunomide | — | — | 26 | 38,8 | — | — |
| Azathioprine | 38 | 32,8 | — | — | — | — |
| Mycophenolate mofetil | 12 | 10,3 | — | — | — | — |
| Biological therapy | — | — | 5 | 7,5 | — | — |
∗Analysis for 44 patients.